An Observational Study to Evaluate Lymph Metastases and Prognoses of the Patients With Esophageal Cancer

Esophageal Cancer Clinical Trial

Official title:

A Real-world Observational Study to Evaluate Lymph Metastases and Prognoses of the Chinese Patients With Thoracic T1-T3 Esophageal Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03415815
• Other study ID #: HenanEC
• Status: Recruiting
• Phase: N/A
• First received: January 11, 2018
• Last updated: January 23, 2018
• Start date: December 12, 2017
• Est. completion date: April 30, 2018

Study information

• Verified date: January 2018
• Source: Henan Cancer Hospital
• Contact: Haiying Yang
• Phone: 0086-10-62680809
• Email: celineyang[@]linkdoc.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The real-world observational study was designed to explore lymph metastases and prognoses of the Chinese patients with thoracic T1-T3 esophageal cancer

Description:

This trial is a real-world non-interventional observational study. The Chinese patients with thoracic T1-T3 esophageal cancer enrolled from Jan.1999 to Jun.2017 were included and the study data on pathologically diagnosed patient demographic/tumor biological characteristics were collected to evaluate the relevance of lymph metastases and prognoses of the subjects.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3673
• Est. completion date: April 30, 2018
• Est. primary completion date: April 30, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients >= 18 years old;

• Patients who received radical resection of esophageal cancer;

• Pathologically diagnosed patients with thoracic T1-T3 esophageal cancer after surgeries;

Exclusion Criteria:

• Patients who received upper gastrointestinal surgeries;

• Patients with second primary tumors;

Related Conditions & MeSH terms

• Esophageal Cancer
• Esophageal Neoplasms

Intervention

Procedure:
• Surgeries
Radical resection of esophageal cancer

Locations

Country	Name	City	State
China	China PLA General Hospital	Beijing	Beijing
China	China-Japan Friendship Hospital	Beijing	Beijing
China	Huaxi Hospital Affiliated to Sichuan University	Chendu	Sichuan
China	First Hospital Affiliated to Zhejiang University	Hangzhou	Zhejiang
China	Jiangsu cancer hospital	Nanjing	Jiangsu
China	Shanghai Chest Hospital	Shanghai	Shanghai
China	Tianjin Chest Hospital	Tianjin	Tianjin
China	Tongji Hospital Affiliated to Huazhong Technology Hospital	Wuhan	Hubei
China	Xi'an Tangdu Hospital	Xi'an	Shaanxi
China	Henan cancer hospital	Zhengzhou	Henan

Sponsors (2)

Lead Sponsor	Collaborator
Henan Cancer Hospital	LinkDoc Technology (Beijing) Co. Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Effects of lymph metastases on overall survival	Effects on lymph metastases on overall survival in the patients with thoracic esophageal cancer	1999 - 2017
Other	Effects of the numbers of lymph nodes on overall survival	Effects of the numbers of lymph nodes on overall survival in the patients with thoracic esophageal cancer who received lymphadenectomy	1999 - 2017
Other	Effects of surgeries on the percentages of the patients with esophageal cancer who received lymphadenectomy	Effects of surgeries on the percentages of the thoracic T1-T3 patients with esophageal cancer who received lymphadenectomy	1999 - 2017
Other	Effects of surgeries on the extents of the patients with esophageal cancer who received surgeries	Effects of surgeries on the extents of the thoracic T1-T3 patients with esophageal cancer who received surgeries	1999 - 2017
Primary	Numbers of lymph nodes and percentages of patients with surgeries	Numbers of lymph nodes and percentages of patients with surgeries in the patients with thoracic T1-T3 esophageal cancer	1999 - 2017
Secondary	Impact factors of lymph metastases	Impact factors of lymph metastases	1999 - 2017